Methods of removing host cell proteins from recombinant protein compositions

Sodium deoxycholate is used to disrupt host cell protein interactions with recombinant polypeptides, enabling effective removal of proteases through chromatography, addressing inefficiencies in existing methods and maintaining antibody integrity and function.

WO2026235944A1PCT designated stage Publication Date: 2026-11-12AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/025386
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-04-27
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods for removing host cell proteins, particularly host cell proteases, from recombinant polypeptides like antibodies are inefficient, often requiring resource-intensive knock-out cell line development or protein engineering, which can alter the antibody's function and structure, and traditional chromatography methods fail to remove tightly bound proteases effectively.

Method used

The use of steroidal compounds, such as sodium deoxycholate, to disrupt host cell protein-recombinant polypeptide interactions, followed by chromatography on a solid support that captures the polypeptide but not the host cell proteins, achieving effective removal under mild pH and salt conditions.

Benefits of technology

This method achieves a significant reduction in host cell proteins, particularly proteases, by up to 50-fold, preserving the integrity and function of the recombinant polypeptides, and is more efficient than traditional methods like sodium caprylate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000011_0001
    Figure IMGF000011_0001
  • Figure IMGF000012_0001
    Figure IMGF000012_0001
  • Figure IMGF000012_0002
    Figure IMGF000012_0002
Patent Text Reader

Abstract

The present disclosure relates to methods for removing host cell proteins, in particular, host cell proteases, from compositions comprising recombinant proteins produced by the host cells.
Need to check novelty before this filing date? Find Prior Art

Description

10006-W001-SECMETHODS OF REMOVING HOST CELL PROTEINS FROM RECOMBINANT PROTEIN COMPOSITIONS

[0001] The benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No.63 / 800,051 filed on May 5, 2025, is hereby claimed.INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0002] Incorporated by reference in its entirety is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: 8,192 bytes (XML) file named "10006-W001-SEC_Sequence_Listing.xml"; created on April 16, 2026FIELD

[0003] The field of this disclosure relates to methods of removing host cell proteins, in particular, host cell proteases, from compositions comprising recombinant polypeptides produced by the host cells.BACKGROUND

[0004] Recombinantly produced polypeptides, such as antibodies, are valuable diagnostic and therapeutic agents. The process of producing recombinant proteins involves expression of the protein in a host cell and isolation of the recombinantly produced protein from the host cell. Recombinantly produced antibodies are secreted from intact host cells; therefore, isolation of the recombinantly produced antibodies is achieved by sedimentation of the cells through centrifugation and retaining cell culture supernatant. However, the supernatant contains impurities, which include host cell proteins (“HCPs”), endotoxins, protein aggregates, DNA and viruses. These impurities must be removed to obtain a fit for purpose recombinant protein product.

[0005] The purification of recombinantly produced polypeptides, such as antibodies, is typically achieved via one or more chromatography steps. For example, a typical purification scheme may include capture of a target recombinant polypeptide, e.g., an antibody, on a protein A (ProA) affinity column to remove the bulk of HCPs, DNA, and viral contaminants. This is followed by polishing steps using affinity, ion exchange (IEX), mixed mode (MM), hydrophobic interaction chromatography (HIC), microfiltration, or any combination thereof to remove protein aggregates, residual HCPs, DNA and endotoxins. However, some low abundance HCPs, such as serine proteases (i.e. trypsin, chymotrypsin) and aspartyl proteases (e.g., Cathepsin B (Cat B) and Cathepsin D (Cat D)) bind tightly to some antibodies and are not removed by the above traditional polishing steps. The tight binding interactions of the HCPs to antibodies is10006-US01-PRItypically attributable to complexes of surface hydrophobic patches with high density electrostatic amino acid clusters. These complexes are referred to as hydrophobic-electrostatic patches. In the case of Cat D-antibody interactions, these complexes are often found in the loops of the complimentary determining regions (CDRs), the hinge region, and the CH3-domain of the antibody. Upon binding to these complexes, the host cell proteases may cleave the antibody, leading to loss of both antibody therapeutic efficacy and structure integrity. Furthermore, the protease generated antibody fragments may self-associate to form toxic immunogenic aggregates. Methods of mitigating protease activity, such as the development of a knock-out protease cell lines have been attempted and have proven effective in mitigating antibody proteolysis. However, knock-out cell line development and validation takes years to establish and is resource intensive. Furthermore, knock-out lines are protease specific. Another mitigation method involves protein engineering where the hydrophobic amino acids at the protease binding site of the antibody are substituted for hydrophilic amino acid residues through mutations. This method can negatively impact the biological function, binding affinity, and / or immunogenicity of the antibody.

[0006] Taken together, there is a need in the art to develop a robust, universal, cost-effective process for eliminating different classes of host cell proteins from compositions comprising recombinantly produced polypeptides, such as antibodies, without altering the manufacturing host cell or sequence architecture of the produced polypeptideSUMMARY OF VARIOUS EMBODIMENTS

[0007] One aspect of the present disclosure is directed to a method for removing host cell proteins (HCPs), including tightly binding host cell proteins, from a preparation comprising a recombinant polypeptide. This method entails contacting a preparation comprising a recombinant polypeptide and HCPs with a solution comprising a steroidal compound, where the steroidal compound disrupts HCP-recombinant polypeptide interactions in the preparation. The method further involves removing the HCPs from the preparation after the contacting step.

[0008] In one embodiment of this aspect of the disclosure, the step of removing the HCPs from the preparation involves loading the preparation, after contacting with the steroidal compound, onto a solid support that is suitable for capturing the recombinant polypeptide but does not capture HCPs. The solid support comprising the captured recombinant polypeptide is washed with one or more wash solutions to remove the residual HCPs from the solid support. The recombinant polypeptide is eluted from the solid support following the wash step.

[0009] In an alternative embodiment of this aspect of the disclosure, the preparation comprising the recombinant polypeptide and HCPs is loaded onto a solid support that is suitable for capturing the10006-US01-PRIrecombinant polypeptide prior to contacting with the steroidal compound. The solution comprising the steroidal compound is added to the solid support containing the recombinant polypeptide to allow the contacting step to be carried out on the solid support. According to this embodiment, the removing step involves washing the solid support with a wash solution to remove HCPs from the solid support after the contacting step, and eluting the recombinant polypeptide from the solid support after the washing step.

[0010] Another aspect of the disclosure is directed to a method of removing HCPs from a preparation comprising a recombinant polypeptide. This method involves contacting a preparation comprising the recombinant polypeptide and HCPs with a solution comprising a carbonate compound, where the carbonate compound disrupts HCP-recombinant polypeptide interactions in the preparation. The method further involves removing HCPs from the preparation after the contacting step.

[0011] In one embodiment of this aspect of the disclosure, removing HCPs from the preparation involves loading the preparation, after contacting with the carbonate compound, onto a solid support that is suitable for capturing the recombinantly produce polypeptide but not the HCPs. The solid support comprising the captured recombinant polypeptide is washed with one or more wash solutions to remove residual HCPs, and the recombinant polypeptide is eluted from the solid support after the washing step.

[0012] In an alternative embodiment of this aspect of the disclosure, the preparation comprising the recombinant polypeptide and HCPs is loaded onto a solid support suitable for capturing the recombinant polypeptide prior to contacting with the carbonate compound. The solution comprising the carbonate compound is added to the solid support containing the recombinant polypeptide to allow the contacting step to be carried out on the solid support. According to this embodiment, the removing step involves washing the solid support with a wash solution to remove HCPs from the solid support after the carbonate contacting step, and eluting the recombinant polypeptide from the solid support after the washing step.

[0013] Another aspect of the present disclosure is directed to a method of producing a preparation comprising an anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody. This method involves contacting a cell culture supernatant comprising the anti-GIPR antibody and host cell proteases with a solution comprising sodium deoxy cholate (DoC), where the DoC disrupts anti-GIPR antibody-host cell protease interactions in the preparation. The method further involves loading the culture supernatant onto an affinity chromatography column, and washing the chromatography column, after being loaded, with one or more wash solutions to remove the host cell proteases from the chromatography column. The anti-GIPR antibody is eluted from the chromatography column thereby producing a preparation of anti-GIPR antibody.10006-US01-PRI

[0014] Prior art methods of removing HCPs from an antibody composition involve chromatographic separation using a mobile phase containing sodium caprylate (Cap), a detergent derived from an octanoic saturated fatty acid. The optimum conditions for HCPs removal from the antibody using sodium caprylate requires an alkaline pH range of 10.0-10.5 in the presence a high salt concentration (i.e., IM NaCl). These extreme conditions were intended to concomitantly disrupt both antibody-HCP hydrophobic and electrostatic interactions through protein deprotonation. However, prolonged exposure of an antibody or other recombinant proteins to extreme alkaline pH can lead to chemical modifications (e.g., amidation) of asparagine amino acids, thereby impacting product quality leading to a potential loss of biological activity. Furthermore, high pH may unfold and destroy the antibody molecular architecture, leading to aggregation.

[0015] The above detriment of using sodium caprylate as a reagent for clearing HCPs from antibody compositions prompted the need to identify compounds having the capacity to eliminate HCPs, in particular host cell proteases, without impacting antibody structure, function, and quality. As described herein, sodium deoxycholate (DoC), a steroidal derivative was selected to clear HCPs due to its strong amphiphilicity and cationic charge moiety that are positioned to disrupt the electrostatic and hydrophobic forces which facilitate host cell protease-antibody complex assembly during antibody expression. Sodium deoxycholate operates in a relatively milder pH range of 7.5- 8.5 and in a lower NaCl concentration range of 0.05-0. IM, and it possesses a high critical micelle concentration for rapid removal from antibody. Moreover, as shown herein, sodium deoxycholate consistently displays superior Cathepsin D clearance from antibody compositions as compared to sodium caprylate. Furthermore, sodium deoxycholate has a favorable FDA safety profile for production of therapeutics.BRIEF DESCRIPTION OF THE FIGURES

[0016] FIG. 1 is a histogram showing the identification of reagents capable of clearing host cell proteases, in particular, Cathepsin D, from cell culture preparations containing a recombinant polypeptide. The x-axis represents Cat D levels in cell culture media (CM) following incubations with the putative Cat D clearing reagents provided along the y-axis. The asterisks show the three compounds with potency to significantly reduce Cat D activity in CM. These compounds, having surfactant properties, were selected to advance to the secondary screening campaign for lead-selection.

[0017] FIG. 2 shows secondary screen purification streams (A through F). The chromatography streams were screened to determine those which most efficiently cleared Cathepsin D from an antibody containing preparation and were adaptable to a large-scale antibody manufacturing processes.10006-US01-PRI

[0018] FIG. 3 is a diagram showing the implementation of ProA column chromatography workflow for screening Cathepsin D clearing reagents.

[0019] FIG. 4 shows the Cathepsin D levels in Pro A eluates collected from the various purification streams outlined in FIG. 2 using the reagents (i.e., sodium deoxy cholate (DoC), sodium carbonate (Na2CCh), and sodium caprylate (Cap)) identified in the screening process (FIG. 1). The x-axis of the histogram shows the average CatD values (ppm / ng protein) and the y-axis shows the purification stream (A-F from FIG. 2). From these screenings, four purification streams reduced Cat D activity to single digit ppm per nanogram levels of total protein from 1424 (ppm) in the CM. These top Cat D clearing purification streams are highlighted by the “check marks” in this figure.

[0020] FIG. 5 provides histogram summaries of Cat D activity and Ab product quality after subjecting antibody containing cell culture media samples to various purification streams. The histogram on the far left shows Cat D activity (ppm) in the samples from the purification stream as noted on the x-axis. The middle histogram shows the percentage levels of monomeric antibody in the ProA eluates from different purification streams identified by analytical size exclusion chromatography (SEC). The latter resolved the ProA eluent constituents on the basis of size. The y-axis of this graph provides main peak (monomer) percentage in each ProA eluate, where the higher the percentage of monomer indicates fewer of both the high molecular weight aggregates (HMW) and low molecular weight (LMW) impurities. The histogram on the right (MCE) shows the percentage HMW and LMW impurities relative to the antibody in the ProA eluates from different purification streams. Here the ProA eluate constituents were separated on an electronic chip where mobility of the constituents was measured as a function size and charge. The y-axis of the graph provides the mean peak percentage of the antibody relative the impurities. Once again, the higher the percentage antibody, the fewer impurities in the eluate.

[0021] FIG. 6 demonstrates Cat D clearance optimization through dynamic sample incubations. Stationary incubation of cell media with sodium carbonate (Na2COs) (i.e., without stirring) yielded a ProA eluate containing 55ppm Cat D activity (CM+NazCCL-Stnd). However, when the ProA eluate was incubated with fresh Na2COs and subject to continuous mixing (Dynamic incubation) for Ihr prior to reloading it onto ProA column, Cat D activity in the second ProA eluate was further reduced from 55 ppm to 31 ppm. Cathepsin D levels in cell media not treated with Na2COs is also shown for comparison (CM-Na2CO3-Stnd).

[0022] FIG. 7 shows a comparison of Cat D clearance by DoC and Cap as measured by RP-HPLC. The graph of FIG. 7 shows the percentage of residual intact Cat D substrate identified by RP-HPLC in ProA eluates following incubation with DoC or Cap.10006-US01-PRIDETAILED DESCRIPTION

[0023] The present disclosure relates to methods of removing host cell proteins (HCPs), particularly host cell proteases, from recombinantly produced polypeptide compositions. The presence of HCPs, like proteases, in recombinant protein preparations are problematic because they can irreversibly impact protein stability, efficacy, and the overall quality of the recombinant protein in the preparation.

[0024] As described herein, recombinantly produced polypeptides are produced in cell cultures. The first step in recovering a recombinantly produced polypeptide from a cell culture is the removal of intact host cells and host cell debris from the culture media to yield a cell culture supernatant that contains the recombinantly produced polypeptide along with other remaining soluble impurities. Harvesting the recombinant polypeptide is generally accomplished by standard methods including, but not limited to, centrifugation, flocculation / precipitation, depth filtration and sterile filtration. Further purification of the recombinant polypeptide from the cell culture supernatant is required to remove impurities such as host cell proteins, DNA, endogenous viruses, endotoxins, aggregates, and other impurities. Most purification methods involve some form of chromatography in which recombinant polypeptides in solution (mobile phase) are separated from the impurities based on differences in chemical or physical interactions with a stationary material (solid phase). Various chromatographic methods for recombinant polypeptide purification are known. These include, but are not limited to affinity, mixed mode, ion exchange, hydrophobic interaction, hydroxyapatite and size exclusion chromatography, gel electrophoresis, dialysis, and combinations thereof. Other techniques for protein purification such as fractionation on an ionexchange column, ethanol precipitation, iso-electric focusing (iEF), Reverse Phase HPLC (RP-HPLC), chromatography on silica, chromatography on heparin, Sepharose chromatography on an anion or cation exchange resin (such as a poly-aspartic acid column), chromato-focusing, and ammonium sulfate precipitation can also be included in the purification process. Often, a combination of different purification processes are coupled together to achieve a purification scheme, such that the different processes separate the recombinant polypeptide from various impurities based on different principles, such as affinity, charge, degree of hydrophobicity, and / or size. The methods of removing host cell proteins as described herein can be added or combined with any of these known methods to significantly improve and enhance the purification of the recombinant polypeptide as compared to a purification scheme that does not include the methods described herein.

[0025] Accordingly, the first aspect of the present disclosure is directed to a method of removing host cell proteins (HCPs) from a preparation comprising a recombinant polypeptide. This method comprises contacting a preparation comprising the recombinant polypeptide and HCPs with a solution comprising a steroidal compound, where the steroidal compound disrupts HCPs-recombinant polypeptide10006-US01-PRIinteractions in the preparation. The method further involves removing the HCPs from the preparation after said contacting.

[0026] In accordance with this and all aspects of the present disclosure, a recombinant polypeptide is an engineered polypeptide or protein produced by a host cell, where the host cell has been stably or transiently transfected with a nucleic acid vector encoding the recombinant polypeptide. Recombinant polypeptides may be expressed by the host cell intracellularly and are often secreted into the culture medium. The recombinantly produced polypeptides can be recovered or collected and subjected to the methods disclosed herein to remove HCPs. Exemplary recombinantly produced polypeptides include, without limitation, antigen binding proteins, e.g., antibodies, engineered antibodies, binding fragments of antibodies, and antibody derivatives; Fc-containing polypeptides; fusion proteins; protein mimetics; full length or active fragments of a protein, e.g., an enzyme, regulatory protein, receptor protein, etc.

[0027] In one embodiment, the preparation comprising a recombinant polypeptide is a preparation comprising an antibody. An “antibody” as referred to herein encompasses immunoglobulin molecules comprising a tetramer composed of two heavy chain polypeptides and two light chain polypeptides. Each heavy chain is comprised of a heavy chain variable (VH) region and a heavy chain constant (CH) region. Each light chain of an antibody is comprised of a light chain variable (VL) region and a light chain constant (CL) region. The variable region contains the complimentary determining regions (CDRs), which are responsible for antibody binding specificity to an antigen. Point mutations in the CDRs can alter or even abolish antibody function. Recombinantly produced antibodies include any of the following isotypes, e.g., IgM, IgD, IgG, IgA, and IgE antibodies. Exemplary recombinant antibody preparations produced using the methods described herein include, without limitation, chimeric, humanized, fully human, and multispecific antibodies, e.g., bispecific antibodies. Exemplary recombinant antibody preparations comprise recombinant mammalian antibodies. In one embodiment, the preparation comprises a recombinantly produced human antibody. In one embodiment, the preparation comprises a human anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody as described in more detail herein.

[0028] In one embodiment, the preparation comprising a recombinant polypeptide is a preparation comprising an antibody fragment. An “antibody fragment” encompasses any polypeptide fragment, region, portion, or domain of a full-length antibody that exhibits some or all of the binding properties of the full-length antibody and can be obtained, for example, by protease cleavage of an intact parental antibody. Exemplary functional immunoglobulin fragments include, but are not limited to, Fab, Fab’, F(ab’)2, Fv, Fd, dAb (single-domain), and antibody fragments comprising an Fc domain.

[0029] In one embodiment, the preparation comprising a recombinant polypeptide is an antibody derivative. An “antibody derivative” is a protein or polypeptide that contains at least one epitope binding10006-US01-PRIdomain of an antibody and is typically formed using recombinant techniques. An antibody derivative comprises an amino acid sequence that is substantially similar to at least a portion of the amino acid sequence of one or more parental antibodies. Exemplary antibody derivatives include, without limitation single chain Fv (scFv), including monospecific and bispecific scFvs. Antibody derivatives further encompass fusion antibodies and antibody conjugates formed within a cell.

[0030] In accordance with the methods described herein, the preparation comprising a recombinant polypeptide and contaminating HCPs is derived from a host cell culture. In one embodiment, the host cell culture is a prokaryotic cell culture. Exemplary prokaryotic host cell cultures suitable for production of a recombinant polypeptide include, without limitation, bacterial cells, such as Escherichia coli, Lactococcus sp. and Bacillus sp., Rodhobacter sphaeroides, Pseudomonas sp., Halomonas elongate, Corynebacterium sp. , and Mycobacterium smegmatis. In one embodiment, the host cell culture is an eukaryotic cell culture. Exemplary eukaryotic host cell cultures suitable for production of a recombinant polypeptide include yeast cells, such asPichia pastoris, Pichia methanolica, and Saccharomyces cerevisiae; insect cells, such as baculovirus; and mammalian cells. Exemplary mammalian cells include, but are not limited to, Chinese hamster ovary (CHO) cells, mouse myeloma (NSO), human embryonic kidney (HEK 293), baby hamster kidney (BHK) cells, Vero cells, HeLa cells, Madin-Darby Canine Kidney (MOCK) cells, CV1 monkey kidney cells, 3T3 cells, myeloma cell lines such as NSO and NS1, PC12, W138 cells, COS cells (including COS-1 and COS-7), and C127. In one embodiment, the mammalian cell culture comprises CHO cells.

[0031] In general, mammalian cell cultures are maintained at a pH between about 6.5 and about 7.5 and at a temperature between about 36°C and about 38°C, typically at about 37°C and a relative humidity between about 80% and about 95%. Mammalian cell culture media typically contains a buffering system that requires a carbon dioxide (CO2) atmosphere between about 1% and about 10%, or between about 5% and about 6%.

[0032] The host cells are maintained in a suitable cell culture media that supports optimal growth and proliferation. Cell culture media formulations are well known in the art, and typically include buffers, salts, carbohydrates, amino acids, vitamins and trace essential elements. The cell culture medium may or may not contain serum, peptone, and / or proteins. Cell culture media may be supplemented with additional or increased concentrations of components such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements and the like, depending on the requirements of the cells to be cultured and / or the desired cell culture parameters. Various culture media, including serum-free and defined culture media, are commercially available, and include, but are not limited to, Minimal Essential Medium (MEM, Sigma, St. Louis, Mo.); Ham's F10 Medium (Sigma); Dulbecco's Modified Eagles10006-US01-PRIMedium (DMEM, Sigma); Minimal Essential Medium (MEM); Basal Medium Eagle (BME); RPMI-1640 Medium (Sigma); HyClone cell culture medium (ElyClone, Logan, Utah); and chemically-defined (CD) media, which are formulated for particular cell types, e.g., CD-CHO Medium (Invitrogen, Carlsbad, Calif.). Supplementary components or ingredients can be added to commercially available media, if desired.

[0033] In one embodiment, the preparation comprising the recombinant polypeptide and contaminating host cell proteins is a cell culture supernatant sample. The cell culture supernatant comprises a physiological solution which the host cells are cultured in (e.g., cell culture media), the secreted recombinant polypeptide of interest, and may also include metabolic byproducts, endogenous proteins of the host cells (i.e., referred to herein as “host cell proteins” or “HCPs”) and other cell debris. As used herein, a “cell culture supernatant sample” refers to this liquid generated in the process of culturing the host cells, where the host cells and cell debris have been removed. Thus, the cell culture supernatant is generally free of cellular debris and / or intact cells. Intact cells and cell debris can be removed to form the cell culture supernatant via centrifugation at low speed (-1500-2000 RPM) for about 5 to 15 minutes.

[0034] The methods of the present disclosure are directed to removing contaminating HCPs from preparations, such as cell culture supernatant samples, comprising a recombinantly produced polypeptide of interest. The methods of removing host cell proteins as described herein are particularly beneficial for preparations comprising a recombinant polypeptide, where the recombinant polypeptide contains surface regions or domains of hydrophobic amino acid residues surrounded by charged amino acids. These hydrophobic surface regions are often referred to as surface hydrophobic patches (SHPs). In recombinant proteins, SHPs may lead to intermol ecul ar associations to form dimers or soluble aggregates particularly at high protein concentrations. Charged (electrostatic) patches are associated with high antibody viscosity values particularly at high protein concentrations. In some instances, SHPs hydrophobically attract and strongly bind HCPs. HCPs interact with recombinant polypeptides via various mechanisms, including, without limitation, electrostatic interactions, hydrophobic interactions, or a combination thereof, in addition to specific sequence based interactions. Therefore, certain HCPs can stick more tightly to recombinant polypeptides than others if the recombinant polypeptides contain one or more regions of surface exposed charged and / or hydrophobic residues. “Sticky” HCPs have a high binding coefficient, which means they have a strong binding interaction with the recombinant polypeptide. For example, Cathepsin D binding constant (Kd) is on the order of 27 x 10‘9nM. These HCPs are particularly problematic contaminants due to their proclivity to resist clearance from the polypeptide of interest by conventional chromatographic polishing steps and washes, e.g., Protein A antibody capture followed by washes containing arginine, isopropanol, NaCl, propylene glycol, Triton X-100, or Tween. More10006-US01-PRIimportantly, if tightly binding proteolytic HCPs are not removed from a preparation they can fragment the recombinant polypeptide into soluble or hydrophobic fragments. The latter may self-associate to form soluble or insoluble aggregates. Examples of these HCPs, which need elimination, include serine proteases, aspartyl proteases, cysteine proteases, metalloproteases and aminopeptidases. In one embodiment, the methods of the present disclosure remove host cell serine proteases, aspartyl proteases, cysteine proteases, metalloproteases and / or aminopeptidases from preparations comprising a recombinant polypeptide. In one embodiment, the methods of the present disclosure remove host cell aspartyl proteases, including, for example, pepsins, cathepsins, and renins, from preparations comprising a recombinant polypeptide. In one embodiment, the host cell protein that is removed from the preparation is a cathepsin. In one embodiment, the host cell protein that is removed from the preparation is cathepsin D.

[0035] As disclosed herein, it was observed that a combination of hydrophobic and electrostatic interactions between recombinantly produced polypeptides and HCPs, such as proteases, were unexpectedly retained during the standard recombinant protein purification processes. Although the resulting HCP levels were relatively low, it nevertheless remained at a level sufficient to persistently fragment the recombinant polypeptide due to proteolytic potency during long term storage. Protein fragmentation becomes more pronounced upon formulation when protein concentration can reach as high as 150-250 mg / mL. In this scenario, the recombinant polypeptide and the contaminating HCP (e.g. protease) are in close proximity thereby accelerating the rate of recombinant polypeptide fragmentation. Thus, the inventors sought and identified a class of agents, i.e., steroidal and carbonate compounds that function as cationic surfactants that are capable of disrupting the hydrophobic interaction between the recombinant polypeptide of interest and host cell protein. While other agents, particularly fatty acid compounds, such as caprylic acid, were previously shown to disrupt this hydrophobic interaction, the effectiveness of caprylic acid is dependent upon high salt and high (alkaline) pH conditions. High salt and high pH conditions can adversely destabilize protein structure through deprotonation of the surface charged amino acids. In contrast, steroidal compounds, afford the same or an enhanced level of host cell protein removal under low to neutral pH conditions (pH 7.5-8.2) and at low salt concentrations (50- 100 mM NaCl).

[0036] In accordance with this and all aspects of the disclosure, the methods of removing host cell proteins from a recombinant polypeptide composition achieves at least or about a 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold and up to 30-fold, 40-fold or 50-fold reduction in the level of host cell proteins, in particular, host cell proteases, in the composition when compared to the level of host cell proteins in the corresponding compositions not treated in accordance with the methods described herein. In other words, the level of host cell protein, in particular, host cell protease, is reduced by 5%, 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or greaterthan 90% as compared10006-US01-PRIto the level of host cell proteins in corresponding compositions not treated in accordance with the methods described herein. The reduction of host cell proteins in a preparation can be measured by a reduction in host cell protein activity. The reduction of host cell protein activity, e.g., protease activity, can be measured using the assay described herein or any suitably sensitive assay, including, for example, EnzChek® Protease Assay Kit E6638 from Molecular Probes (Eugene, OR). Any assay that can reliably detect or quantify levels of >10 ng / mL of proteases such as the aspartyl protease, Cathepsin-D, or the serine protease in control preparations is suitable for quantitating of host cell proteolytic activity.

[0037] In one embodiment, the host cell protein that is removed from a preparation comprising a recombinant polypeptide using the methods described herein is a host cell protease. The methods described herein achieve at least or about a 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or greater than 90% reduction of protease levels in the recombinant polypeptide containing composition compared to the level of host cell proteases in corresponding compositions not treated in accordance with the methods described herein. In one embodiment, the methods described herein achieve at least or about a 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or greater than 90% reduction of protease cleavage, e.g., Cathepsin D cleavage, of the recombinant polypeptide in treated preparations compared to the level of protease cleavage of the recombinant polypeptide in corresponding preparations not treated in accordance with the methods described herein. Methods for detecting protease mediated cleavage of a recombinant polypeptide substrate are known in the art and described herein.

[0038] Accordingly, in one embodiment, the method of removing host cell proteins, such as host cell proteases, from a preparation comprising a recombinant polypeptide involves contacting the recombinant polypeptide containing preparation with a solution comprising a steroidal compound. As referred to herein, a “steroidal compound” is any compound possessing the characteristic parent tetracyclic steroid structure, which comprises three fused six-membered rings and one five-membered ring. This structure is known as the steroid nucleus and is exemplified by Gonane (cyclopentanoperhydrophenanthrene) as shown below.H(cyclopentanoperhydrophenanthrene)10006-US01-PRI

[0039] In one embodiment, suitable steroidal compounds for use in the methods of the present disclosure are bile salts. Bile salts encompass a family of steroidal compounds comprising the characteristic tetracyclic structure of Gonane (above) with a five- or eight-carbon side-chain terminating in a carboxylic acid, and several hydroxyl groups as shown in the structure below. Suitable bile acid compounds for use in the methods described herein include, without limitation, cholic acid, deoxycholic acid, chenodeoxycholic acid (CDCA), glycocholic acid, taurocholic acid, Na-taurocholate, glycodeoxy cholic (GDCA), glycochenodeoxycholic acid (GCDCA), taurodeoxycholic acid (TDCA), Na-taurodeoxycholate, taurochenodeoxycholic acid (TCDCA), lithochohc acid, ursodeoxycholic acid, salts thereof, and derivatives thereof such as CHAPS and CHAPSO surfactants.0Bile Acid

[0040] In one embodiment, a suitable steroidal compound for use in the methods of the present disclosure is the deoxycholic acid (DoCA) derivative, sodium deoxycholate (DoC). DoC is steroidal amphiphilic molecule consisting of a bulky hydrophobic tetracyclic steroid nucleus which is fused to a polar short carbon atom fatty acid chain. The latter renders solubility to this compound in aqueous solutions.Deoxycholic acid10006-US01-PRINa+O'HSodium Deoxy cholate

[0041] Accordingly, in one embodiment, the method of removing host cell proteins from a preparation comprising a recombinant polypeptide involves contacting the preparation with a solution comprising the steroidal compound, e.g., deoxy cholic acid, to disrupt host cell protein-recombinant protein interactions in the preparation. In one embodiment, this contacting is carried out in solution. Following the contacting, the mixture of the recombinant polypeptide preparation and a solution comprising the steroidal compound is loaded onto a solid support suitable for capturing the recombinant polypeptide but not the host cell proteins. Accordingly, HCPs are not captured on the solid support and are cleared from the preparation comprising the recombinant polypeptide. The solid support comprising the captured recombinant polypeptide is washed with one or more wash solutions to remove any residual host cell proteins. The recombinant polypeptide is subsequently eluted from the solid support after the wash step.

[0042] In exemplary embodiments, the method involves contacting the recombinant polypeptide preparation with a solution comprising a steroidal compound selected from deoxycholic acid, deoxycholate, sodium glycochneodeoxycholate, sodium glycocolate hydrate, sodium glycodeoxycholate, sodium taurodeoxycholate, taurocholic acid sodium hydrate, sodium taurocholate hydrate, or any combination thereof. In exemplary embodiments, the method involves contacting the recombinant polypeptide preparation with a solution comprising deoxycholic acid. In exemplary embodiments, the method involves contacting the recombinant polypeptide preparation with a solution comprising sodium deoxy cholate.

[0043] In exemplary embodiments, the method involves contacting the recombinant polypeptide preparation with a solution comprising the steroidal compound, e.g., sodium deoxycholate, where the ratio of steroidal compound to total protein in the recombinant polypeptide preparation is 1.0 to 5.0. In exemplary embodiments, the ratio of steroidal compound to total protein is 1.5 to 3.0. In exemplary embodiments, the ratio of steroidal compound to recombinant polypeptide is 1.5 to 3.5. In exemplary10006-US01-PRIembodiments, the ratio of steroidal compound to recombinant polypeptide is 1.0 to 1.5. In exemplary embodiments, the ratio of steroidal compound to recombinant polypeptide is 1.0 to 2.0. In exemplary embodiments, the ratio of steroidal compound to recombinant polypeptide is 1.0 to 2.5. In exemplary embodiments, the ratio of steroidal compound to recombinant polypeptide is 1.0 to 3.0. In exemplary embodiments, the ratio of steroidal compound to recombinant polypeptide is 1.0 to 4.0. In exemplary embodiments, the ratio of steroidal compound to recombinant polypeptide is 1.0 to 5.0.

[0044] In exemplary embodiments, the concentration of sodium deoxycholate in the solution is about ImM to about 50mM, more preferably about 5 mM to about 25 mM. In one embodiment, the concentration of the sodium deoxy cholate in the solution is about 10 mM to about 15 mM. These values are within the solubility range of sodium deoxycholate in solution at room temperature. In exemplary embodiments, the solution comprising sodium deoxycholate further comprises a salt. In one embodiment, the salt concentration in the contacting solution is <1 M. In one embodiment, the salt concentration is less than 0.5 M. In one embodiment, the salt concentration is about 0.05 M to about 0.5 M. In one embodiment, the salt in the contacting solution is sodium chloride. In one embodiment, the concentration of sodium chloride in the contacting solution is about 0.05 M to about 0.5 M. In one embodiment, the concentration of sodium chloride in the contacting solution is about 0.05 M to about 0.1 M.

[0045] Contacting the preparation comprising the recombinant polypeptide with the solution comprising the steroidal compound is carried out under conditions suitable for the steroidal compound to disrupt or disassociate the interactions between the recombinant polypeptide and the contaminating host cell proteins. In one embodiment, the contacting is carried out for a duration of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 minutes or longer than 60 minutes. In exemplary embodiments, the contacting is carried out for a duration of 60 minutes to 120 minutes. In exemplary embodiments, the contacting is carried out at room temperature and at a pH of between 7.0 and 9.5. In exemplary embodiments, the contacting is carried out at a pH of between 7.5 and 8.5. In exemplary embodiments, the contacting is a dynamic contacting, i.e., the preparation comprising the recombinant polypeptide and steroidal compound is mixed for part of or all of the contacting duration.

[0046] As noted above, in one embodiment, following contacting with a steroidal compound, the resulting preparation comprising the recombinant polypeptide and steroidal compound is loaded onto a solid support, where the solid support is suitable for capturing the recombinant polypeptide, but not host cell proteins. In one embodiment, the solid support comprises an affinity chromatography medium, e.g., an affinity chromatography column or affinity chromatographic resin. In one embodiment, the affinity chromatography medium comprises a ligand that binds an Fc- and / or hinge-containing polypeptide, a ligand that binds an antibody, a ligand that binds a heavy chain polypeptide, or a ligand that binds a light10006-US01-PRIchain polypeptide. In one embodiment, the affinity chromatography medium comprises a ligand that binds a heavy chain constant region, e.g., CHI, or a kappa light chain. Suitable affinity chromatography ligands include, without limitation, Protein A and Protein G, which are bacterial proteins that bind to the Fc region of immunoglobulins; artificial protein A (ApA); Protein A-Dura Cycle; Protein A / G, which is a fusion protein of Proteins A and Gthat also binds the Fc region and hinge region of immunoglobulins; Protein L, which is another bacterial protein that binds kappa variable light chains of immunoglobulins; and artificial protein L (PpL). In one embodiment, the solid support is a Protein A column, in particular a Protein A-Dura Cycle column. Other suitable affinity ligands for immobilization of antibodies and antibody fragments include the lectin, jacalin; M protein family members; protein Sir22; protein Arp4; and the hexamer peptide ligand HWRGWV (SEQ ID NO: 5). Additional affinity ligands that can be employed in the solid support material used in the methods described herein include immobilized metal ions. Chelating ligands, such as iminodiacetic acid (IDA) or nitrilotn acetic acid (NTA), generate metal ions (e.g., Ni2+, Zn2+, Co2+, Cu2+, and Fe2+) on the solid phase matrix to facilitate the affinity binding of these metal ions to amino acid side chains or termini of amino acids in the recombinant polypeptide, e.g., histidine residues (e.g., polyhistidine tag), serine residues, aspartate residues, cysteine residues, glutamate residues, methionine residues, tyrosine residues, and tryptophan residues within the recombinant polypeptide (e.g., antibody or antibody fragment). Other affinity ligands suitable for capturing and immobilizing the recombinant polypeptides as described herein are described in Cassedy and O’Kennedy, AFFINITY CHROMATOGRAPHY METHODS AND PROTOCOLS in Methods in Molecule Biology (Springer Science, 2022). In one embodiment, the solid support utilized in the methods described herein is a Protein A chromatography column, e.g., a Protein A-Dura Cycle column.

[0047] In general, the preparation comprising the recombinant polypeptide and steroidal compound is loaded onto the solid support at a concentration of the recombinant polypeptide of at least about 1 mg / ml, 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml or 25 mg / ml and up to about 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml. In one embodiment, the recombinant polypeptide is loaded onto the solid support at a concentration of about 30 mg / ml to about 45 mg / ml. In one embodiment, the recombinant polypeptide is loaded onto the solid support at a concentration of about 5 mg / ml to about 20 mg / ml. In one embodiment, the preparation comprising the recombinant polypeptide and steroidal compound is diluted with a loading buffer at a ratio of about 1:1, 1:2 or 1:3, for example, to achieve a desired concentration for the recombinant polypeptide and / or to adjust the pH of the solution. In other embodiments, the preparation comprising the recombinant polypeptide and steroidal compound is loaded directly onto the column (i.e., without dilution in a loading buffer). In general, the recombinant polypeptide is loaded onto the solid support at a pH of about 6.0 to a pH of about 9.0. In one embodiment, the10006-US01-PRIrecombinant polypeptide is loaded onto the solid support at a pH of at least about 7.0 to a pH of about 8. In some embodiments, the loading buffer is the same as the equilibration buffer. In other embodiments, the loading buffer and the equilibration buffer are not the same. In other embodiments, the loading buffer is also used as a wash buffer to wash the column after loading.

[0048] In one embodiment, the solid support is an affinity chromatography column. In one embodiment, the solid support is a Protein A affinity chromatography column. The flow rate of the recombinant polypeptide / steroid compound preparation through an affinity chromatography column, like a Protein A column, is an important parameter for optimizing recombinant polypeptide binding and separation from HCPs. Although a reduced separation time may be desirable, a flow rate that is too fast may accelerate through the stationary phase faster than the diffusion time needed for the recombinant polypeptide to bind the ligand. Generally, a flow rate of at least about 100 cm / hour or 150 cm / hour and up to about 300 cm / hour, 350 cm / hour, 400 cm / hour, 450 cm / hour, 500 cm / hour, 550 cm / hour, 600 cm / hour, 650 cm / hour, or 700 cm / hour is used depending on the diameter of the column. In one embodiment, the flow rate is between 100 cm / hour and 200 cm / hour. The column dimensions can also be varied. In one embodiment, the column is for lab scale production having a diameter of about 1 cm to about 5 cm. In one embodiment, the column is for large scale production having a diameter of about 1 meter to about 2 meters. For large scale or commercial production, the column bed height is generally at least about 10 cm, 15 cm or 20 cm, and up to about 25 cm or 30 cm.

[0049] In one embodiment, the solid support, e.g., a Protein A chromatographic column, is equilibrated with an equilibration buffer prior to loading the preparation comprising the recombinant polypeptide and steroidal compound. In one embodiment, the equilibration buffer includes sodium chloride and / or tris(hydroxymethyl)aminomethane (Tris). In one embodiment, the equilibration buffer includes sodium phosphate. In exemplary embodiments, the equilibration buffer includes the steroidal compound used to disrupt the recombinant polypeptide-host cell protein interactions, e.g., sodium deoxy cholate. In one embodiment, the equilibration buffer includes about 10 mM to about 200 mM of sodium chloride. In one embodiment, the equilibration buffer includes about 50 mM to about 100 mM sodium chloride at a pH between about 6 and about 8. In one embodiment, the equilibration buffer includes about 50mM to about 150 mM sodium chloride at a pH between about 7 and about 8. In one embodiment, the equilibration buffer includes about 100 mM sodium chloride at a pH of about 7.4.

[0050] After the preparation comprising the recombinant polypeptide and steroidal compound is loaded on to the solid support to immobilize the recombinant polypeptide, the solid support is subjected to one or more washes to remove residual host cell proteins. In exemplary embodiments the one or more wash solutions comprise an arginine containing wash solution. In exemplary embodiments, the10006-US01-PRIconcentration of arginine in the wash solution is about 0.1 M to about 1 M. In exemplary embodiments, the concentration of arginine in the wash solution is about 0.1 M to about 0.5 M. Alternatively, the one or more wash solutions comprise a sodium deoxycholate containing wash solution. In exemplary embodiments, the concentration of sodium deoxycholate in the wash solution is about 2 rnM to about 50 mM. In exemplary embodiments, the concentration of sodium deoxycholate in the wash solution is about 10 mM to about 40 mM. In exemplary embodiments, the concentration of sodium deoxy cholate in the wash solution is about 15 mM to about 30 mM. Alternatively, the one or more wash solutions comprises a sodium carbonate containing wash solution. In exemplary embodiments, the concentration of sodium carbonate in the wash solution is about 25 mM to about 250 mM. In exemplary embodiments, the concentration of sodium carbonate in the wash solution is about 75 mM to about 150 mM. In exemplary embodiments, the one or more wash solutions comprises a first sodium deoxycholate containing wash solution and a second sodium carbonate containing wash solution. In exemplary embodiments, the first sodium deoxy cholate containing wash solution comprises a concentration of about 10 mM to about 25 mM sodium deoxycholate and the second sodium carbonate containing wash solution comprises a concentration of about 25mM to about 150 mM sodium carbonate. The concentrations of these clearing agents are a function of a total protein concentration to maintain a reproducible optimized surfactant-to-protein ratio for HCP clearance from different batches of expressed antibody.

[0051] In one embodiment, the method further includes optional second, third, and fourth wash steps following the wash with the sodium deoxycholate and / or sodium carbonate wash solutions. Additional wash steps may employ wash solutions comprising sodium chloride (about 50mM to about 500 mM), sodium phosphate (about 10 mM to about 100 mM), arginine or arginine derivatives (0.5 M to about 2 M). Suitable arginine derivatives include, without limitation, acetyl arginine, N-alpha-butyroyl-arginine, agmatine, arginmic acid and N -alpha-pivaloyl arginine. The pH of one or more wash buffers is preferably about 7.0 to about 8.0. The one or more wash solutions may include one or more additives to increase protein solubility, including, NaCl, KC1, and (NH^SCh.

[0052] Following the step of washing the solid support to remove residual HCPs, the recombinant polypeptide is eluted from the solid support with an elution buffer. The term “elution buffer” refers to a buffer used to elute (i.e., remove or release) the target recombinant polypeptide from the solid support column. In exemplary embodiments, the elution buffer comprises sodium acetate. In exemplary embodiments, the elution buffer comprises between 50 mM and 100 mM sodium acetate. In exemplary embodiments, the elution buffer comprises glycine. In exemplary embodiments, the elution buffer comprises between 50 mM and 100 mM glycine. Alternatively suitable elution buffers include buffers10006-US01-PRIcontaining sodium citrate, citric acid, acetic acid, sodium mono-phosphate, or combinations thereof at a concentration of at least about 25 mM or 50 mM and up to about 100 mM, 150 mM or 200 mM.

[0053] The elution buffer pH can vary depending upon the binding affinity of the recombinant polypeptide to the solid support. Some recombinant polypeptides, which possess a higher binding affinity, may require a lower elution pH. In general, the pH of the elution buffer is lower than the pH of the loading buffer. Typically, the elution buffer has a pH of at least about 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, or 3.5 and up to about 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.5, 4.7, 4.8. In exemplary embodiments, the elution buffer comprises a pH of about 3.0 to about 4.8. In exemplary embodiments, the elution buffer comprises a pH of about 3.0 to about 3.7. In exemplary embodiments, the elution buffer comprises about 100 mM sodium acetate at a pH of 3.2 to 3.7. In exemplary embodiments, the elution buffer comprises about 100 mM glycine at a pH of 2.7 to 3.7. Elution buffers may include one or more additives such as, e.g., polysaccharides to protect the recombinant polypeptide from low pH induced denaturation, and NaCl to increase protein solubility.

[0054] An exemplary method of removing host cell proteins, in particular host cell proteases like cathepsin D, from a preparation comprising an antibody involves contacting a cell culture supernatant comprising the antibody and host cell proteases with a solution comprising sodium deoxycholate (DoC), where the DoC disrupts the antibody -host cell protease interactions in the preparation. The ratio of DoC to total protein in the recombinant antibody preparation is preferably 1.0 to 5.0, more preferably, the ratio of DoC to total protein is 1.5 to 3.0. The method further involves loading the culture supernatant treated with DoC onto an affinity chromatography column, and washing the chromatography column, after being loaded, with one or more wash solutions to remove the host cell proteases from the chromatography column. In one embodiment, the one or more wash solutions comprises an arginine containing wash solution, where the arginine is at a concentration of about 0.1 M to about 0.5 M in the wash solution. Alternatively, the one or more wash solutions comprise a sodium deoxycholate containing wash solution, where the sodium deoxy cholate is at a concentration of about 15 mM to about 30 mM in the wash solution. The antibody is eluted from the chromatography column thereby producing a preparation of antibody substantially free of host cell proteases, in particular cathepsin D.

[0055] In an alternative embodiment of this method to remove host cell proteins from a recombinant polypeptide preparation, the preparation comprising the recombinant polypeptide and host cell proteins is first loaded onto a solid support suitable for capturing the recombinant polypeptide. After the preparation comprising the recombinant polypeptide and host cell proteins is loaded onto the solid support, the solution comprising the steroidal compound is added to the solid support. This approach allows the contacting step (i.e., contacting the preparation comprising the recombinant polypeptide and10006-US01-PRIHCPs with a solution comprising a steroidal compound) to occur on the solid support. Suitable solid supports for capturing the recombinant polypeptide are described supra.

[0056] In accordance with this alternative embodiment, where the preparation comprising the recombinant polypeptide and host cell proteins is loaded onto a solid support and the preparation is contacted with the steroidal compound on the solid support, the concentration, pH, and loading parameters of the recombinant polypeptide onto the solid support is as described supra. In exemplary embodiments, at least about 1 mg / ml, 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml or 25 mg / ml and up to about 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml of recombinant polypeptide is loaded onto the solid support. In exemplary embodiments, the recombinant polypeptide is loaded onto the solid support at a concentration of about 5 mg / ml to about 20 mg / ml. In exemplary embodiments, the preparation comprising the recombinant polypeptide is diluted with a loading buffer at a ratio of about 1:1, 1 :2 or 1 :3, for example, to achieve a desired concentration for the recombinant polypeptide for its optimum retention on the solid support under pre-set column flow rate and pH. In other embodiments, the preparation comprising the recombinant polypeptide and host cell proteins is loaded directly onto the column (i.e., without dilution in a loading buffer). The recombinant polypeptide is loaded onto the solid support at a pH of about 6.0 to a pH of about 9.0. In exemplary embodiments, the recombinant polypeptide is loaded onto the solid support at a pH of at least about 7.0 to a pH of about 8.

[0057] In one embodiment, the solution comprising the steroidal compound that is added to the solid support comprising the recombinant polypeptide, comprises sodium deoxycholate. The solution comprises a sodium deoxycholate concentration sufficient to achieve a ratio of steroidal compound to recombinant polypeptide of about 1.0 to about 5.0. In exemplary embodiments, the ratio of steroidal compound to recombinant polypeptide is about 1.5 to about 3.0. Exemplary sodium deoxy cholate solutions for application to the solid support to achieve this ratio comprise about 1 mM to about 50 mM sodium deoxycholate, or about 10 mM to about 25 mM sodium deoxycholate. In one embodiment, the solution comprising sodium deoxycholate further comprises a salt. In one embodiment, the salt concentration in the solution is <1M. In one embodiment, the salt concentration is less than 0.5M. In one embodiment, the salt concentration is about 0.05M to about 0.9M, 0.05M to about 0.8M, 0.05M to about 0.7M, 0.05M to about 0.6M, 0.05M to about 0.5M, 0.05M to about 0.4M, 0.05M to about 0.3M, 0.05M to about 0.2M, or 0.05M to about 0. IM. In one embodiment, the salt in the solution is sodium chloride. In one embodiment, the concentration of sodium chloride in the solution is about 0.05M to about 0.5M. In one embodiment, the concentration of sodium chloride in the solution is about 0.05M to about 0.1M.

[0058] In one embodiment, contacting on the solid support is carried out for a duration of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 minutes or longer than 60 minutes. In one embodiment, contacting on10006-US01-PRIthe solid support is carried out for a duration of at least or equal to one hour via continuous flow of 1, 2, 3, 4, 5, or more column volumes (CVs) of the steroidal solution, e.g., sodium deoxycholate containing solution. In one embodiment, the contacting is carried out at room temperature and at a pH of between 7.0 and 9.5. In one embodiment, the contacting is carried out at a pH of between 7.5 and 8.5.

[0059] This embodiment of the method further involves washing the solid support with a wash solution to remove host cell proteins from the solid support after the contacting step, i.e., after the steroidal compound has disrupted the recombinant polypeptide-host cell protein interactions on the solid support. In one embodiment, the wash solution comprises sodium carbonate. In one embodiment, the concentration of the sodium carbonate in the wash solution is about 25mM to about 0.1M. Finally, the recombinant polypeptide is eluted from the solid support after the one or more washes. In one embodiment, the recombinant polypeptide is eluted using a sodium acetate elution buffer as described supra.

[0060] Another aspect of the present disclosure is directed to a method of removing HCPs from a preparation comprising a recombinant polypeptide that involves contacting the recombinant polypeptide preparation with a carbonate compound as an alternative to the steroidal compound. In particular, this method involves providing a preparation comprising the recombinant polypeptide and HCPs and contacting the preparation with a solution comprising a carbonate compound, where the carbonate compound disrupts HCP-recombinant polypeptide interactions in the preparation. This method further involves removing host cell proteins from the preparation after the contacting step.

[0061] Accordingly, in one embodiment, this method of removing HCPs from a preparation comprising a recombinant polypeptide involves contacting the recombinant polypeptide composition with a solution comprising a carbonate compound. As referred to herein, a “carbonate compound” is any compound possessing the characteristic carbonate group (O=C(-O-)2. Suitable carbonate compounds include, without limitation, sodium carbonate (Na2CO?), sodium bicarbonate (NaHCCh), ammonium carbonate ((NH^COs), potassium carbonate (K2CO3), and derivatives and salts thereof. In one embodiment, the carbonate compound is sodium carbonate.

[0062] In one embodiment, this method involves contacting the recombinant polypeptide preparation with a solution comprising a carbonate compound selected from sodium carbonate, sodium bicarbonate, ammonium carbonate, potassium carbonate. In one embodiment, the method involves contacting the recombinant polypeptide preparation with a solution comprising a carbonate compound, where the ratio of the carbonate compound to total protein (recombinant polypeptide plus other proteins) in the preparation is 1.0 to 5.0. In exemplary embodiments, the ratio of carbonate compound to total protein in the preparation is 1.5 to 3.0. In exemplary embodiments, the ratio of carbonate compound to recombinant polypeptide is 1.0 to 1.5. In exemplary embodiments, the ratio of carbonate compound to10006-US01-PRIrecombinant polypeptide is 1.0 to 2.0. In exemplary embodiments, the ratio of carbonate compound to recombinant polypeptide is 1.0 to 2.5. In exemplary embodiments, the ratio of carbonate compound to recombinant polypeptide is 1.0 to 3.0. In exemplary embodiments, the ratio of carbonate compound to recombinant polypeptide is 1.0 to 4.0. In exemplary embodiments, the ratio of carbonate compound to recombinant polypeptide is 1.0 to 5.0. In exemplary embodiments, the method involves contacting the recombinant polypeptide preparation with a solution comprising sodium carbonate, where the ratio of sodium carbonate to recombinant polypeptide is 1.5 to 3.0. In exemplary embodiments, the method involves contacting the recombinant polypeptide preparation with a solution comprising sodium carbonate where the concentration of sodium carbonate in the solution is about 1 mM to about IM, about 10 mM to about 0.5M, about 25mM to about 0.25M, about 50mM to about 0.1M. In exemplary embodiments, the concentration of the sodium carbonate in the solution is about 50 mM to about 0.1 M in the solution. In exemplary embodiments, the solution comprising sodium carbonate further comprises a salt. In exemplary embodiments, the salt concentration in the solution is <1M. In one embodiment, the salt concentration in the solution is less than 0.5M. In one embodiment, the salt concentration in the solution is about 0.05M to about 0.5M. In exemplary embodiments, the salt in the solution is sodium chloride. In exemplary embodiments, the concentration of sodium chloride in the solution is about 0.05M to about 0.5M. In exemplary embodiments, the concentration of sodium chloride in the solution is about 0.05M to about 0.1M.

[0063] Contacting the preparation comprising the recombinant polypeptide with the solution comprising the carbonate compound is carried out under conditions suitable for the carbonate compound to disrupt the interactions between the recombinant polypeptide and the contaminating HCPs. In exemplary embodiments, the contacting is carried out for a duration of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 minutes or longer than 60 minutes. In exemplary embodiments, the contacting is carried out for a duration of at least or equal to 60 minutes and up to 120 minutes. In exemplary embodiments, the contacting is carried out at room temperature and at a pH of between 7.0 and 9.5. In exemplary embodiments, the contacting is carried out at a pH of between 7.5 and 8.5, which is also the optimum solubility range of sodium carbonate and antibody stability. In exemplary embodiments, the contacting is a dynamic contacting, where the preparation comprising the recombinant polypeptide and carbonate compound is mixed or stirred for part of, or all of, the contacting duration.

[0064] Following contacting the recombinant polypeptide preparation with the carbonate compound, the preparation comprising the recombinant polypeptide and carbonate compound is loaded onto the solid support, where the solid support is suitable for capturing the recombinant polypeptide, but not the host cell protein. In one embodiment, the solid support comprises an affinity chromatography10006-US01-PRImedium, e.g., an affinity chromatography column or affinity chromatographic resin. In one embodiment, the affinity chromatography medium comprises a ligand that binds an Fc containing polypeptide, a ligand that binds a hinge-containing ligand, a ligand that binds an antibody, a ligand that binds a heavy chain polypeptide, a ligand that binds the hinge region of an antibody, or a ligand that binds a light chain polypeptide. Suitable affinity mediums are described supra. In one embodiment, the solid support in a Protein A chromatography column.

[0065] In one embodiment, the preparation comprising the recombinant polypeptide and carbonate compound is loaded onto the solid support as described supra, e.g., at a concentration of the recombinant polypeptide of at least about 1 mg / ml, 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml or 25 mg / ml and up to about 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml. In one embodiment, the recombinant polypeptide is loaded onto the solid support at a concentration of about 5 mg / ml to about 20 mg / ml. In one embodiment, the recombinant polypeptide is loaded onto the solid support at a concentration of about 5 mg / ml to about 10 mg / ml. In one embodiment, the preparation comprising the recombinant polypeptide and carbonate compound is diluted with a loading buffer at a ratio of about 1:1, 1:2 or 1:3, for example, to achieve a desired concentration for the recombinant polypeptide and / or to adjust the pH of the solution. In other embodiments, the preparation comprising the recombinant polypeptide and carbonate compound is loaded directly onto the column (i.e., without prior dilution in a loading buffer). In general, the recombinant polypeptide is loaded onto the solid support at a pH of about 6.0 to a pH of about 9.0. In one embodiment, the recombinant polypeptide is loaded onto the solid support at a pH of about 7.0 to a pH of about 8. In some embodiments, the loading buffer is the same as the equilibration buffer. In other embodiments, the loading buffer and the equilibration buffer are not the same. In other embodiments, the loading buffer is also used as a wash buffer to wash the column after loading.

[0066] After the preparation comprising the recombinant polypeptide and carbonate compound is loaded on to the solid support, the solid support is subject to one or more washes to remove residual, dissociated HCPs. In one embodiment the one or more wash solutions comprise a carbonate compound, e.g., a 25 mM to 500 mM sodium bicarbonate containing wash solution, more preferably a 50 mM to 150 mM sodium carbonate containing wash solution. In another embodiment, the one or more wash solutions comprise a steroidal compound, e.g., a 10 mM to 50 mM sodium deoxycholate containing wash solution, more preferably a 25 mM to 50 mM sodium deoxy cholate containing wash solution. In exemplary embodiments the one or more wash solutions comprise an arginine containing wash solution. In exemplary embodiments, the concentration of arginine in the wash solution is about 0.1 M to about 1 M. In exemplary embodiments, the concentration of arginine in the wash solution is about 0.1 M to10006-US01-PRIabout 0.5 M. In one embodiment, the one or more wash solutions comprise a fatty acid containing wash solution. Suitable fatty acids or fatty acid salts for inclusion in the wash buffers of the methods disclosed herein include, but are not limited to, fatty acids having a chain length of at least about 6, 7, 8 or 9 carbon atoms and up to about 10, 11 or 12 carbon atoms, or fatty acid salts thereof including, but not limited to, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylenic acid, lauric acid or combinations and salts thereof. In one embodiment, the fatty acid containing wash solution contains caprylic acid. In one embodiment, the fatty acid containing wash solution contains 25 mM to 100 mM of the fatty acid, e.g., 25 mM to 100 mM of caprylic acid.

[0067] In exemplary embodiments, the one or more wash solutions comprise a first carbonate containing wash solution and a second fatty acid containing wash solution. In exemplary embodiments, the one or more wash solutions comprise a first sodium carbonate containing wash solution and a second caprylic acid containing wash solution. In exemplary embodiments, the one or more wash solutions comprise a first sodium carbonate containing wash solution, a second caprylic acid containing wash solution, and a third arginine containing wash solution.

[0068] In exemplary embodiments, the one or more wash solutions comprises a first carbonate compound containing wash solution and a second steroidal compound containing wash solution. In exemplary embodiments, the one or more wash solutions comprise a first sodium carbonate containing wash solution and a second sodium deoxy cholate containing wash solution. In exemplary embodiments, the one or more wash solutions comprise a first sodium carbonate containing wash solution, a second sodium deoxycholate containing wash solution, and a third arginine containing wash solution.

[0069] As described supra, wash buffers may include one or more additives to increase protein purity, stability, and function, including, but not limited to osmolytes, such as glycerol, detergents, and sugars to stabilize protein structure or ionic stabilizers, including amino acids, such as histidine, and salts, such as NaCl and KC1 to enhance solubility.

[0070] Following the step of washing the solid support to remove residual host cell proteins, the recombinant polypeptide is eluted from the solid support with an elution buffer. In one embodiment, the elution buffer comprises sodium acetate. In one embodiment, the elution buffer comprises between 50 mM and 100 mM sodium acetate. Typically, the elution buffer has a pH of at least about 3.0, 3.1, 3.2, 3.3, 3.4, or 3.5 and up to about 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.5, 4.7, 4.8. In one embodiment, the elution buffer comprises a pH of about 3.0 to about 4.0. In one embodiment, the elution buffer comprises a pH of about 3.0 to about 3.5. In one embodiment, the elution buffer comprises about 100 mM sodium acetate at a pH of 3.0 to 3.5.10006-US01-PRI

[0071] Alternatively, the elution buffer comprises glycine. In one embodiment, the elution buffer comprises between 50 mM and 100 mM glycine at a pH of about 2.7 to about 3.7. In another embodiment, the elution buffer comprises citric acid. In one embodiment, the elution buffer comprises between 50 mM to 100 mM of citric acid at pH of about 2.3 to about 3.7.

[0072] As described supra, elution buffers may include one or more additives to increase protein purity, stability, and function, including, but not limited to osmolytes such as glycerol, detergents and sugars, such as polysaccharides to stabilize protein structure or ionic stabilizers, including amino acids and salts.

[0073] An exemplary method of removing host cell proteins, in particular host cell proteases like cathepsin D, from a preparation comprising an antibody involves contacting a cell culture supernatant comprising the antibody and host cell proteases with a solution comprising sodium carbonate, where the sodium carbonate disrupts the antibody-host cell protease interactions in the preparation. The ratio of sodium carbonate to total protein in the recombinant antibody preparation is preferably 1.0 to 5.0, more preferably, the ratio of sodium carbonate to total protein is 1.5 to 3.0. The method further involves loading the culture supernatant treated with sodium carbonate onto an affinity chromatography column, and washing the chromatography column, after being loaded, with one or more wash solutions to remove the host cell proteases from the chromatography column. In one embodiment, the one or more wash solutions comprise a carbonate compound, e.g., a 50 mM to 150 mM sodium carbonate containing wash solution. In one embodiment, the one or more wash solutions comprise a steroidal compound, e.g., a 25 mM to 50 mM sodium deoxy cholate containing wash solution. In one embodiment, the one or more wash solutions comprise an arginine containing wash solution, e.g., 0.1 Mto 0.5 M arginine containing wash solution. In one embodiment, the one or more wash solutions comprise a fatty acid containing wash solution. In one embodiment, the fatty acid containing wash solution contains 25 mM to 100 mM of caprylic acid. Following washing, the antibody is eluted from the chromatography column thereby producing a preparation of antibody substantially free of host cell proteases, in particular cathepsin D.

[0074] In an alternative embodiment of this aspect of the present disclosure, the method to remove host cell proteins from a recombinant polypeptide composition involves loading the preparation comprising the recombinant polypeptide and HCPs onto a solid support suitable for capturing the recombinant polypeptide prior to contacting the preparation with the carbonate containing solution. In this embodiment, the solution comprising the carbonate compound is added to the solid support containing the loaded recombinant polypeptide and HCPs. This approach allows the contacting step (i.e., contacting the preparation comprising the recombinant polypeptide and HCP with the solution comprising a carbonate10006-US01-PRIcompound) to occur on the solid support. Suitable solid supports for capturing the recombinant polypeptide are described supra.

[0075] In one embodiment, the carbonate compound of the solution comprises sodium carbonate. The solution comprises a sodium carbonate concentration sufficient to achieve a ratio of carbonate compound to recombinant polypeptide of about 1.0 to about 5.0. In exemplary embodiments, the ratio of carbonate compound to recombinant polypeptide is about 1.5 to about 3.0. Exemplary sodium carbonate solutions for application to the solid support to achieve this ratio comprise a concentration of sodium carbonate in the solution of about 1 mM to about IM, about 10 mM to about 0.5M, about 25mM to about 0.25M, about 50mM to about 0. IM. In one embodiment, the concentration of the sodium carbonate in the solution is about 50 mM to about 0.1 M in the solution. In one embodiment, the solution comprising sodium carbonate further comprises a salt. In one embodiment, the salt concentration in sodium carbonate solution added to the solid support is <1M. In one embodiment, the salt concentration is less than 0.5M. In one embodiment, the salt concentration is about 0.05M to about 0.5M. In one embodiment, the salt in the sodium carbonate solution is sodium chloride. In one embodiment, the concentration of sodium chloride in the solution is about 0.05M to about 0.5M. In one embodiment, the concentration of sodium chloride in the solution is about 0.05M to about 0.1M.

[0076] In one embodiment, contacting on the solid support is carried out for a duration of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 minutes or longer than 60 minutes. In one embodiment, contacting on the solid support is carried out for a duration of at least or equal to one hour via continuous flow of 1, 2, 3, 4, 5, or more column volumes (CVs) of the carbonate compound composition, e.g., sodium carbonate containing solution. In one embodiment, the contacting is carried out at room temperature and at a pH of between 7.0 and 9.5. In one embodiment, the contacting is carried out at a pH of between 7.5 and 8.5.

[0077] This embodiment of the method further involves washing the solid support with a wash solution to remove host cell proteins from the solid support after the contacting step, i.e., after the carbonate compound has disrupted the recombinant polypeptide-host cell protein interactions. In one embodiment, the wash solution comprises a steroidal compound. In one embodiment, the wash solution comprises sodium deoxycholate. In one embodiment, the concentration of the sodium deoxycholate in the wash solution is about 2 mM to about 20 mM. In another embodiment, the wash solution comprises a fatty acid compound. In one embodiment, the wash solution comprises caprylic acid. In one embodiment, the concentration of the caprylic acid in the wash solution is about 10 mM to about 50 mM.

[0078] Finally, the recombinant polypeptide is eluted from the solid support after the one or more washes. In one embodiment, the recombinant polypeptide is eluted using a sodium acetate elution buffer10006-US01-PRIas described supra. Alternatively, the recombinant polypeptide is eluted using a glycine elution buffer, a citric acid elution buffer, or an acidified sodium mono-phosphate elution buffer as described supra.

[0079] Another aspect of the present disclosure is directed to a method of producing a preparation of an anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody. This method involves contacting a cell culture supernatant comprising the anti-GIPR antibody and host cell proteases with a solution comprising sodium deoxycholate, wherein the sodium deoxycholate disrupts anti-GIPR antibodyhost cell protease interactions in the preparation. The method further involves loading the culture supernatant, after being contacted with the sodium deoxy cholate solution, onto an affinity chromatography column. The chromatography column is washed, after the loading step, with one or more wash solutions to remove the HCP from the chromatography column, and the anti-GIPR antibody is eluted from the chromatography column thereby producing a preparation of anti-GIPR antibody. This anti-GIPR antibody preparation is substantially free of host cell proteases like cathepsin D.

[0080] Suitable anti-GIPR antibodies that can be produced and purified from HCPs host cell proteins, e.g., HCP, in accordance with the methods disclosed here include any anti-GIPR antibody known in the art, because the methods described herein are applicable to any antibody. In any embodiment, the anti-GIPR antibody is any one of the anti-GIPR antibodies disclosed in U.S. Patent No. 10,294,303, which is hereby incorporated by reference in its entirety. In one embodiment, the anti-GIPR antibody comprises a light chain variable region amino acid sequence of SEQ ID NO: 1. In one embodiment, the anti-GIPR antibody comprises a heavy chain variable region amino acid sequence of SEQ ID NO: 2. In one embodiment, the anti-GIPR antibody comprises a light chain variable region amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region amino acid sequence of SEQ ID NO: 2. In one embodiment, the anti-GIPR antibody comprises a light chain amino acid sequence of SEQ ID NO: 3. In one embodiment, the anti-GIPR antibody comprises a heavy chain ammo acid sequence of SEQ ID NO: 4. In one embodiment, the anti-GIPR antibody comprises a light chain amino acid sequence of SEQ ID NO: 3 and a heavy chain amino acid sequence of SEQ ID NO: 4.SEQ IDAnti-GIPR Ab SequenceNO:EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPG VL QAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFA 1VYYCQQYNNWPLTFGGGTKVEIKR QVQLVESGGGWQPGRSLRLSCAASGFTFSNYGMHWVRQA VH PGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLY 2LQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPG LC QAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFA 3VYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQL10006-US01-PRISEQ IDAnti-GIPR Ab SequenceNO:KSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT KSFNRGEC QVQLVESGGGWQPGRSLRLSCAASGFTFSNYGMHWVRQA PGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLY LQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQS SGLYSLS SVVTVPS SSLGTQTYIC NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF HC 4LFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGV EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0081] As used herein, a preparation comprising an anti-GIPR antibody that is “substantially free of’ host cell protease refers to a preparation where the anti-GIPR antibody is the predominant species present and host cell proteases comprises less than 20%, less than 15%, less than 10%, less than 5%, or less than 1% of the preparation. In one embodiment, the anti-GIPR antibody is purified using the method described herein to essential homogeneity, i.e., the presence of contaminant host cell proteases cannot be detected in the composition by conventional detection methods. In one embodiment, the host cell protease that is removed from the anti-GIPR antibody preparation is a serine protease, an aspartyl protease, a cysteine protease, a metalloprotease, or an aminopeptidases. In one embodiment, the host cell protease that is removed from the anti-GIPR antibody preparation is an aspartyl protease, including, for example, a pepsin, a cathepsin, and / or a renin. In one embodiment, the host cell proteases that is removed from the anti-GIPR antibody preparation is a cathepsin. In one embodiment, the host cell protease that is removed from anti-GIPR antibody preparation is cathepsin D.

[0082] Prior art methods of removing host cell proteins, particularly proteases, from monoclonal antibody compositions involved chromatographic separation coupled with exposure to a wash buffer comprising a fatty acid such as sodium caprylate. However, the use of sodium caprylate has a number of disadvantages. Firstly, it is a weak detergent and, therefore, not efficient at disrupting the association between host cell proteins and antibodies. To the extent it is useful in disrupting HCP-antibody interactions, such activity requires high salt concentrations and high pH levels, both of which can be detrimental to antibody structure and function. In contrast, as described herein, it has been found that steroidal compounds, such as sodium deoxycholate, can more potently disrupt hydrophobic HCP-antibody10006-US01-PRIinteraction (3-fold improvement in HCP removal) under comparatively lower salt and pH conditions. Additionally, sodium deoxycholate and other steroidal molecules comprise a high critical micelle concentration, which allows such steroidal compounds to be easily washed out and removed during the purification process, saving time and money.

[0083] The invention having been described, the following examples are offered by way of illustration, and not limitation.10006-US01-PRIEXAMPLESExample 1: Materials and Methods

[0084] Materials: The composition of stock solutions for incubations with cell culture media (CM), Protein A (Pro A) column chromatography, and elution buffers are provided in Table 1 below. The stock solutions were serially diluted with 1 M Tris-HCL, pH 8.2 stock buffer to obtain the working solutions shown in Table 2. Aliquots from the stock buffer were also used to prepare CM incubations with the HCP clearing agent prior to loading onto ProA column.Table 1. Composition of stock solutionsSolution Description Composition(1) Antibody 4 Liters of mAb (5 mg / ml)(2a) Wash 0.025 M Tris-HCL, 0.1 M NaCl, pH 8.2(2b) Wash 0.025 M Tris-HCL, 2.5 M NaCl, pH 9.0(3) Na2CO31 M Na2CO30.1 M Tns-HCl, 0.15 M NaCl, pH 8.2(4) Na-Deoxy cholate (DoC) 0.125 M DoC 0.025M Tns-HCl, 0.15M NaCl, pH 8.2(5) Na-Caprylate (Cap) 0.1 M Cap:0.1MTris (1: 1), 0.05M sodium caprylate, 2.5 MNaCl, pH 9.0(6) Stnd HCP Clearing solution 0.025 M Tns-HCl, 0.5 M Arginine, pH 7.5(7) Ab eluting solution from ProA 0. IM Na-acetate, pH 3.6(8) Ab neutralizing solution 2M Trizma base(9) Column cleaning solution A 0. IM Phosphoric acid(10) Column cleaning solution B O.lMNaOHTable 2. Composition of ProA Column Washing Solutions for HCP removalProA Column Wash CompositionNa2CO30.025 M Tns-HCl, 0.1 M Na2CO3, 0. IM NaCl, pH 8.2DoC 0.025 M Tns-HCl, 0.020 M Na-deoxycholate, 0. IM NaCl, pH 8.2 Cap 0.025 M Tns-HCl, 0.050 M Na-caprylate, 0.1 M NaCl pH 9.0

[0085] Cathepsin D (Cat D) Plate-based Activity Assay. Cathepsin D activity was measured in cell culture media (CM) and ProA eluates in the presence or absence of putative Cat D clearing reagents using a plate-based fluorescence assay. Culture media samples with the clearing reagents were diluted over10006-US01-PRIa 100-fold to minimize their potential back ground effects on the assay. Additionally, CM dilution brought Cat D levels within a readable linear range of the fluorescent signal. Both filtered crude cell culture medium (feed into ProA high-trap column) and ProA eluates (following column washing with different buffers) were diluted to a uniform protein concentration with 0. IM sodium acetate, pH 3.5 (the optimum pH Cat D proteolytic activity) before subjecting them to the time course Cat D assay.

[0086] The assay was initiated by mixing 15 pL of the protein test samples with 35 pL lysate buffer in a black, clear-well bottom 96-format titer plate. Cat D standards were prepared using 15 pL 0.1 M sodium acetate buffer and 35 pL Cat D solution in a commercial lysate buffer. The five standards were prepared at the linear range of 0.13 ng to 2.5 ng. Separately, 0.1 M sodium acetate buffer, pH 3.5, was mixed with (1 mM) Cat D peptide fluorescent substrate (as described by the manufacturer) in a buffer: substrate ratio of 50:2 proportional to the number of wells to be tested (i.e., 5 mL buffer to 200 pL substrate for 100 wells). The substrate solution was mixed into each well (of a 96-format titer plate) carefully to avoid foaming. The test samples, each containing a ProA column eluate which had been mixed with the designated putative Cat D clearing reagent, were added to the substrate containing wells of the plate. The fluorescent peptide substrate digests by Cat D were measured at an excitation of 328 nm and an emission 460nm starting at time 0, followed by 30-minute interval read-outs over a 2 hour period. Due to the linearity of the substrate hydrolysis curves within the first 60-minute of the reaction, the data points in this time frame were selected to quantify Cat D levels in each treatment. Data from this analysis was expressed in a histogram shown in FIG. 1.

[0087] Antibody quantitation: The quantity of purified antibody in the column fractions was determined by measuring the absorbance of the eluates at 280nm wavelength using a 96-format plate reader. The A280 values from these measurements were converted to mg of antibody through multiplication by a standard molar ellipticity of I.29mg / ml @ 280nm for IgGl subtypes (see Maity et al., Int J Biol Macromol 77:260-5 (2015)).

[0088] Protein A Column Separation: As described herein and shown in FIG. 2, cell culture media samples comprising antibody were subject to various purification streams. These purification streams generally involved (i) contacting the CM with candidate Cat D clearing reagent, (ii) subjecting the CM sample containing the Cat D clearing reagent to chromatography separation (Pro A column), and (iii) contacting the ProA column with various washes to remove Cat D and other host cell proteins from the sample. Some purification streams bypassed the culture media incubation step, and others did not involve chromatographic separation. Protein chromatography was performed using a semi -automated Fast Protein Liquid Chromatography (FPLC) system. Table 3 shows the operating parameters which were used to10006-US01-PRIscreen the lead surfactants for Cat D clearing efficiency from GIPR antibody using ProA column chromatography.

[0089] The details of the chromatographic workflow are depicted in FIG. 3. Briefly the column was equilibrated with 3 column volumes (CV) of buffer # 1 (25 mM Tris, 100 mM NaCl, pH 7.4). Following equilibration, 5 mL of the diluted culture media sample containing antibody and clearing regent was loaded onto the column. The column was subsequently subjected to a standard wash solution (containing arginine) or a combination of washes as outlined in the FIG. 2. The composition of wash solutions (i.e., Na2CO?, DoC, and Cap washes) containing the clearing reagents and volumes of wash solutions used in these purification streams is provided in Table 2 above and shown in FIG. 3. Following the washes, the antibody was eluted from the column using 100 mM Na Acetate buffer (pH 3.6). The collected treated CM or ProA eluate was analyzed for Cat D activity and product quality utilizing the various assays described herein. Across the different ProA purification streams, sodium deoxycholate consistently displayed better Cat D clearance activity than caprylic acid. This result was validated by the following three distinct Cat D activity assays: 1. Fluorescent plate assay, 2. RP-HPLC and 3. RP-HPLC / LCMS.Table 3. Chromatography hardware and parametersChromatography hardware Processing parametersResin Mab select sureResin binding capacity 60mg / mlColumn size 5mlResin volume load 5mlBed height 2.5cmFlow rate 150cm / hrElution mode IsocraticChromatography device AKTA pure™

[0090] Analytical size exclusion chromatography for purity assessment: Analytical size exclusion chromatography was performed using aHPLC 1100 Agilent system which was equipped with a ACQUITY UPLC Protein BEH SEC Column (200 A, 1.7 pm, 4.6 mm X 150mm). The mobile phase was 50mM MES / 0.1M NaCl, pH 6.5. Purity of the antibody was measured by integrating the A280nm10006-US01-PRIabsorbance profile peaks. The percentage of main peak in the elution profile, as analyzed by the software, was translated to percentage antibody purity in the ProA eluates.

[0091] Micro-capillary electrophoresis (MCE) to measure antibody clipping: Lab CHIP GXII MCE system was used to detect and quantify potential antibody clipping by cell culture proteases during production. This quantitative SDS-PAGE method also measured the percentage of low molecular weight impurities (labeled as post main peak) and was performed according to the manufacturer’s instructions (Caliper Life Sciences, Inc. , Hopkinton, MA).

[0092] Liquid chromatography, mass spectrometry (LC-MS / MS) detection of peptide substrate hydrolysis by CatD. A 20 min LC-MS / MS run was set up to monitor both intact Cat D substrate peptide [1-47] and the proteolytically generated peptides species following incubation with ProA column eluates or commercial Cat D control. An Agilent 1290 Infinity II UPLC was coupled to a Thermo Q-Exactive Plus Hybrid Quadrupole Orbitrap mass spectrometer using the standard HESI II ionization interface. Peptide digests were separated using a Waters BEH 2.1mm X 150 mm 1.7pm particle size Cl 8 column run at 50°C. The UPLC mobile phases were as follows. A: 0.1% formic acid / water and B: 0.1% formic acid / acetonitrile. The resulting LC-MS / MS data were first screened to identify any clipped peptide species based upon high-resolution, high mass accuracy HCD fragment ion spectra criteria. Full MS data from T8-14 min of the same LC-MS / MS runs was then deconvoluted (time ranges T8-14 minutes) using the Xtract utility of the Thermo Excalibur software to yield the relative distribution of the different intact and clipped peptide species. Observed clipped peptide species included [1-22], [23-47], [26-47], [1-13], [14-22], [1-25], and [10-47], This qualitative data was used to determine both the cleavage sites and relative degree by which the intact peptide was degraded by Cat D activity during the 20min incubation in buffers of different pHs at 37°C.

[0093] Time course analysis of peptide substrate hydrolysis by Cat D using a Reversed phase-high performance liquid chromatography ( RP-HPLC) method. In this experiment, RP-HPLC was in principle performed as described above in LC-MS method (Hamazaki et al., FEBS Letters 396: 139-142 (1996)). In this experiment, a short Cathepsin D peptide substrate was used for RP-HPLC detection of Cat D activity in ProA column eluates that were obtained after washing using NaiCOy DoC and Cap. Incubations of the substrate peptide with the ProA column eluates were performed as described above in the fluorescent plate-based assay for Cat D with the exception that the incubations were terminated after 24hrs.10006-US01-PRIExample 2: Processes for Removing Host Cell Proteases from Antibody Preparations

[0094] Some antibodies contain surface hydrophobic-patches which exist in close proximity to electrostatic patches (EPs). When both complexes are in close proximity to each other, they present a very strong sticky binding patch complex for some HCPs including host cell proteases, such as cathepsin D. These sticky binding sites may reside in the CDRs where they may have evolved specifically to bind the epitopes of antigens. In the present study, the binding of Cat D to an exemplary antibody (anti-GIPR antibody) was confirmed by its substrate specificity and its inhibition profile by Pepstatin inhibitor. Furthermore, the Cat D protease activity could not be removed from the antibody through the traditional antibody manufacturing purification platform. Microcapillary electrophoresis (MCE) analysis did not show any sign of antibody clipping by Cat D. However, the protease was cleaving a pharmacologically specific linker peptide which was coupled to an engineered cysteine of the antibody to form the anti-GIPR antibody -peptide conjugate molecule. From these observations it was inferred that the protease was carried over from the antibody preparation, i.e., the protease was a remnant of the host cells that produced the antibody and was not removed via the standard antibody purification steps. The objective of the present study was to eliminate Cat D from the antibody containing preparation prior to the antibody-peptide conjugation process to improve long-term stability and efficacy of the resulting antibody-peptide conjugate.

[0095] A small library of buffered candidate reagents was subject to a primary screen to identify those reagents having the ability to disrupt Cat D-antibody interactions or having an inhibitory effect on Cat D (FIG. 1). The rank order of Cat D clearing / inhibitory activity of these candidate reagents was established in cell media samples containing antibody incubated with the candidate reagents using the Cat D plate-based fluorescence time course activity assay as described supra. From these screens, it was found that Na-carbonate (NazCCE), Na-deoxycholate (DoC), and Na-caprylate (Cap) containing buffers were capable of significantly reducing Cat D activity in the antibody containing cell medium (see the histogram of FIG. 1). These compounds possess cationic-surfactant properties. Both their surface-active properties and negative electrostatic properties can concomitantly disrupt hydrophobic and electrostatic proteinprotein interactions reminiscent of sodium dodecyl sulphate (SDS) but at a milder non-protein denaturing level.

[0096] Na2CO is a “pseudo-surfactant” also known as “soda ash”. This compound, due to its alkalinity, is used in anti-acid tablets for indigestion treatment. Additionally, Na2CO is used to treat metabolic acidosis. In research, Na2CO buffer has been employed to extract and solubilize surface membrane proteins. Na-caprylate (Cap) is a fatty acid salt derivative of Caprylic acid. Na-deoxycholate,10006-US01-PRI(DoC) is a bile salt derivative of a sterol. It is secreted by the gall balder for lipid digestion. Unlike Na2C0, Cap and DoC are surfactants whose amphiphilic property disrupts hydrophobic protein-protein interactions in aqueous solutions without inducing protein denaturation in aqueous solutions.

[0097] The impact of Na2COs, DoC, and Cap on Cat D clearance from antibody containing preparations was further examined in duplicate experiments using various Protein A (ProA) affinity chromatography purification streams (FIG. 2). Table 4 shows how the cell culture medium (CM) containing antibody was proportionately mixed with the candidate clearing reagents (NazCOs, DoC, or Cap) for pre-incubations prior to chromatography. The clearing reagent-to-total antibody ratios were implemented in the incubations and in ProA column washing solutions. These ratios, shown in Table 4, were within the linear detergent: protein ratio range of 1: 1-3: 1 traditionally used in solubilizing membrane proteins.Table 4Antibody / Cat D Stock Weight of Clearing Diluting Final Dilution Clearing Solution Solution key agent: Ab buffer volume factor (mL) ingredient ratio (mL) (mL)(mg)Stock mAb (5mg / ml) 9 45 0 20 29 3.2 pH 7.2 (in 0.025MTns-HCL / 0.15MNaCl)0.1MNa2CO3, pH 8.2 6.5 68.9 1:1.5 13.5 20 3.1 (10.6mg / ml)0.025 MNa- 10.4 110.6 1:2.4 9.6 20 1.92 Deoxycholate, pH 8.2(10.36mg / ml)0.05 M Caprylic Acid, 13 112.1 1:2.4 7 20 1.5 pH 9.0 (8.62mg / ml)

[0098] Several purification streams (A through F) were developed to screen for the most efficient means for clearing Cat D from an antibody preparation (FIG. 2). In purification test stream A, the cell culture media comprising an antibody was incubated with each of the candidate clearing reagents (z.e., Na2COs, DoC, or Cap) without subjecting the mixtures to downstream column purification and compared10006-US01-PRIto buffer treatment alone. The purpose of stream A was to determine whether these surfactants had an inhibitory effect on Cat D activity during the assay. This stream, which was used as a control experiment for the subsequent chromatography screens, was analogous to the primary screen experiment shown in FIG 1.

[0099] In test stream B, cell culture media containing antibody was contacted with each of the candidate clearing reagents or buffer alone. Following incubation, the treated culture media was loaded onto the ProA column and subjected to the standard column wash containing arginine (0.5M arginine, pH 7.5) (“Stnd”).

[0100] In test stream C, cell culture media containing antibody was contacted with each of the candidate clearing reagents or buffer alone. The treated culture media was loaded onto the ProA column and subjected to a first Na2COs wash followed by a second standard column wash (Stnd).

[0101] In test stream D, cell culture media containing antibody was contacted with Na2CO? as the candidate clearing reagents or buffer alone. The treated culture media was loaded onto the ProA column, subjected to a first Na2COs wash, a second DoC or Cap wash, and a third standard column wash.

[0102] In test stream E, cell culture media containing antibody was contacted with DoC as the candidate clearing reagents or buffer alone. The treated culture media was loaded onto the ProA column, subjected to a first DoC wash, and a second standard column wash or a second Na2COs wash, followed by a third standard column wash.

[0103] Finally, in test stream F, cell culture media containing antibody was contacted with Cap as the candidate clearing reagents or buffer alone. The treated culture media was loaded onto the ProA column and subjected to a first Cap wash and a second standard column wash or a first Cap wash and a second Na2COs wash.

[0104] Details of the wash buffer compositions, volumes, and sequence of washes is provided in FIGs. 2 and 3 and Table 2. The solutions in Table 2 were derived by serial dilution from the stock solutions presented in Table 1. The ProA eluates of each purification stream sample were analyzed for Cat D activity and product quality using the fluorescence plate-based Cat D assay together with micro-capillary exclusion chromatography (MCE) and analytical size exclusion chromatography (SEC) (described above).

[0105] Treatment of culture media containing antibody with DoC followed by ProA chromatography yielded ProA eluate having significantly reduced Cat D levels (8 ppm). The Cat D levels were 10-fold higher in the Na2COs treatment (83 ppm) and 3 -fold higher in the Na-caprylate (“Cap”) (29ppm) purification streams respectively (FIG. 4, stream B), thus highlighting DoC as an effective clearing reagent for Cat D removal from recombinant protein containing preparations.10006-US01-PRI

[0106] The effect of serially washing the ProA column using NazCOz followed by either DoC or Cap was also investigated. Incubation of the culture media with NazCOz followed by loading the mixture onto ProA affinity column and consecutively washing the column with NazCOz, Cap, and a standard wash (CM+ NazCOz^ NazCOz - Cap Stnd, purification stream D) lowered Cat D levels from 1424 ppm in the culture media to background levels of 3ppm in the ProA eluate (see FIG. 4 compare CM sample from stream A to the CM+ NazCOz^ NazCOz-^Cap->Stnd sample from stream D). Additionally, the antibody quality obtained from this purification stream was superior to those of mAb-ProA eluates recovered after washing the column using other buffer regimens as shown by size exclusion chromatography (SEC), which measure percentage of antibody monomer in the ProA eluate (see middle graph of FIG. 5), and microcapillary electrophoresis (MCE), which measures the percentage of intact antibody in the ProA eluate (see right graph of FIG. 5). Neither NazCOz (83ppm) nor Cap (29ppm) alone was able to clear Cat D to single digit levels (stream B). From this result, it was concluded that NazCOz synergistically enhances Cap’s potency in clearing Cat D from the antibody containing culture media preparation. This synergistic effect of NazCOz did not extend to DoC. As shown in FIG. 4, culture media incubation with NazCOz followed by NazCOz, DoC, and Stnd washes (CM+NazCOz^NazCOz^DoC^Stnd, stream D) yielded a ProA eluate which contained a Cat D level of lOppm. This value was higher than the Cat D levels (8ppm) obtained from DoC incubation followed by standard wash (CM + DoC -> Stnd, stream B),

[0107] The order of NazCOz in the purification sequence was also important as shown in FIG. 4, where treatment of culture media with NazCOz. followed by a NazCOz and Cap washes (CM + NazCOz^ NazCOz ->Cap->Stnd, purification stream D) was superior to Cap CM treatment alone (CM + Cap->Stnd, purification stream B) or Cap CM treatment plus a NazCOz wash (CM + Cap- NazCOz ->Stnd), purification stream C). In fact, CM treatment with NazCOz, followed by a NazCOz and Cap washes was the most effective purification stream for clearing Cat D from the antibody preparation.

[0108] A summary of Cat D clearance and antibody product quality from the tested purification streams is provided in FIG. 5. The graphs show Cat D activity (FIG. 5, far left graph), percentage of monomeric antibody by SEC (FIG. 5, middle graph), and the amount of intact antibody by MCE (FIG. 5, graph far right). These data indicate that: (1) CM treatment with DoC, which reduced Cat D activity to 8 ppm, is the most practical purification stream for manufacturing processes (FIG. 5, far left graph, sample # 3 (CM + DoC -> Stnd)). This stream combined a robust optimizable Cat D clearance method which reduced Cat D activity from 1424ppm to 8ppm using both low cycle time and low cost of goods (COGs). Cell media treatment with DoC required only an incubation step of culture media with DoC prior to loading onto the Pro A column and was followed by a single washing step with standard wash buffer. (2) Culture treatment with NazCOz followed by NazCOz, Cap, and standard column washes with ProA purification10006-US01-PRIwas complex to execute. However, it reduced Cat D activity from 1424 ppm to near a baseline Cat D at 3ppm (see FIG. 5, far left graph, sample #6 (CM + Na2CO3Na2CO3 ->Cap-> Stnd)). The antibody purified by this method also possessed higher quality attributes (i.e., low aggregation and a low level of impurities) (see FIG. 5, middle SEC graph, sample 6 and far right MCE graph, sample 6) than the antibody purified by other ProA column washing streams for Cat D clearance.

[0109] In a separate experiment, the impact of re-incubating a ProA eluate with Na2CO3 by stirring was investigated. When a ProA eluate containing 55 ppm of Cat D activity was incubated with Na2CO3with continuous stirring and re-purifying over ProA, an almost 2-fold reduction in Cat D levels (31ppm) in the second Pro A eluate was observed (see FIG. 6). From this result, it was concluded that continuous stirring of the clearing reagent with the cell culture media enhances Cat D clearance from an antibody containing preparation and likely applies not only to Na2CO3, but also DoC.

[0110] In conclusion, culture media treatment with DoC (plus ProA separation and single standard wash) demonstrated a 3.5-fold superior Cat D removal capacity (Cat D activity of 8 ppm) as compared to similar treatment with Cap (Cat D activity of 29 ppm). The superiority of DoC vs. Cap for removing CatD was further confirmed by RP-HPLC analysis of intact CatD substrate in ProA eluates following incubation with DoC or Cap as shown in FIG. 7 (86% intact substrate in DoC treated eluates vs. 75% intact substrate in Cap treated eluates). The simplicity of this treatment paradigm, i.e., not requiring serial washings, is favored from a manufacturing perspective (providing a low cycle time and reduced cost of goods).

[0111] The results herein show that incubation of CM with Na2CO3 followed by washing the ProA column with Na^CO? and Cap respectively, was the most efficient method for clearing Cat D from antibody preparations. Starting from Cat D activity level of 1424 ppm in untreated CM, this workflow reduced Cat D level in ProA eluates to 3 ppm. This translates to a 475-fold reduction in Cat D levels. Additionally, the antibody preparation from this workflow also exhibited lower HMW aggregate levels (SEC) and fewer low molecular weight impurities (MCE) than mAb products from other workflows. Finally, dynamic incubation of antibody containing preparation with the clearing regent (e g., DoC or Na2CO3) enhances Cat D clearance efficiency over static CM incubations.Table 5. Summary of the Three Leading Purification StreamsPurification Work CM+DoC-»Stnd CM+ Na2CO3■» CM+ Na2CO3■» Flow Na2CO3-^Cap-^Stnd Na2C03->DoC->Stnd Cat D levels (ppm) 8 3 10Application to 95% 25% 25% ManufacturingMonomer levels (SEC) 76% 87% 86%10006-US01-PRIMain peak (MCE) 90% 94% 94%

[0112] Each reference cited herein is hereby incorporated by reference in its entirety for all that it teaches and for all purposes.

[0113] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual embodiments of the invention, and functionally equivalent methods and components are invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

Claims

10006-W001-SEC CLAIMS1. A method of removing host cell proteins (HCPs) from a preparation comprising a recombinant polypeptide, said method comprising:contacting a preparation comprising the recombinant polypeptide and HCPs with a solution comprising a steroidal compound, wherein the steroidal compound disrupts HCP-recombinant polypeptide interactions in the preparation; andremoving HCPs from the preparation after said contacting.

2. The method of claim 1, wherein said removing comprises:loading the preparation, after said contacting, onto a solid support suitable for capturing the recombinant polypeptide but not the HCPs;washing the solid support comprising the captured recombinant polypeptide with one or more wash solutions to remove residual HCPs; andeluting, after said washing, the recombinant polypeptide from the solid support.

3. The method of claim 2, wherein said one or more wash solutions comprise a sodium deoxycholate containing wash solution.

4. The method of claim 2, wherein said one or more wash solutions comprise a sodium carbonate containing wash solution.

5. The method of claim 2, wherein said one or more wash solutions comprise a first sodium deoxycholate containing wash solution and a second sodium carbonate containing wash solution.

6. The method of claim 2, wherein said one or more wash solutions comprise an arginine containing wash solution.

7. The method of any one of claims 2-6, wherein said eluting is carried out with a sodium acetate solution having a pH of 3.0 to 3.7.

8. The method of claim 1 further comprising:loading, prior to said contacting, the preparation comprising the recombinant polypeptide and HCPs onto a solid support suitable for capturing the recombinant polypeptide;adding the solution comprising the steroidal compound to the loaded solid support, wherein said contacting is carried out on the solid support; andwherein said removing comprises:10006-US01-PRI washing, after said contacting, the solid support with a wash solution to remove the HCPs from the solid support; andeluting, after said washing, the recombinant polypeptide from the solid support.

9. The method of claim 8, wherein said wash solution is a sodium bicarbonate containing wash solution.

10. The method of any one of claims 1-9, wherein said contacting is earned out at a pH of between 7.0 and 9.5.

11. The method of any one of claims 1-10, wherein the steroidal compound of the solution is deoxycholate or a derivative thereof.

12. The method of claim 11, wherein the deoxy cholate or derivative thereof is sodium deoxycholate.

13. The method of claim 12, wherein the sodium deoxycholate is at a concentration of about 1 mM to about 50 mM in the solution.

14. The method of any one of claims 10-12, wherein the solution further comprises sodium chloride at a concentration of about 0.05 M to about 0.5 M.

15. A method of removing host cell proteins (HCPs) from a preparation comprising a recombinant polypeptide, said method comprising:contacting a preparation comprising the recombinant polypeptide and HCPs with a solution comprising a carbonate compound, wherein the carbonate compound disrupts HCP-recombinant polypeptide interactions in the preparation; andremoving HCPs from the preparation after said contacting.

16. The method of claim 15, wherein said removing comprises:loading the preparation, after said contacting, onto a solid support suitable for capturing the recombinantly produce polypeptide but not the HCPs;washing the solid support comprising the captured recombinant polypeptide with one or more wash solutions to remove residual HCPs; andeluting, after said washing, the recombinant polypeptide from the solid support.10006-US01-PRI17. The method of claim 16, wherein said one or more wash solutions comprise a first sodium bicarbonate containing wash solution and a second fatty acid containing wash solution.

18. The method of claim 17, wherein the fatty acid containing wash solution is a caprylic acid wash solution.

19. The method of claim 16, wherein said one or more wash solutions comprise a first sodium bicarbonate containing wash solution and a second sodium deoxycholate containing wash solution.

20. The method of claim 15 further comprising:loading, prior to said contacting, the preparation comprising the recombinant polypeptide and HCPs onto a solid support suitable for capturing the recombinant polypeptide;adding the solution comprising the carbonate compound to the loaded solid support, wherein said contacting is carried out on the solid support;wherein said removing comprises:washing, after said contacting, the solid support with a wash solution to remove HCPs from the solid support; andeluting, after said washing, the recombinant polypeptide from the solid support.

21. The method of claim 20, wherein said wash solution is a sodium deoxycholate containing wash solution.

22. The method of claim 20, wherein said wash solution is a fatty acid containing wash solution.

23. The method of claim 22, wherein the fatty acid containing wash solution is a caprylic acid wash solution.

24. The method of any one of claims 15-23, wherein said contacting is carried out at a pH of between 7.0 and 9.5.

25. The method of any one of claims 15-24, wherein the carbonate compound in the solution is sodium carbonate.

26. The method of claim 25, wherein the sodium carbonate is at a concentration of about 50 mM to about 0.1 M in the solution.10006-US01-PRI27. The method of claim 25, wherein the solution further comprises sodium chloride at a concentration of about 0.05 M to about 0.5 M.

28. The method of any one of claims 1-27, wherein the HCPs in the preparation comprise one or more proteases.

29. The method of claim 28, wherein the one or more proteases is selected from serine proteases, aspartyl proteases, cysteine proteases, metalloproteases, aminopeptidases, and combinations thereof.

30. The method of claim 29, wherein the one or more proteases is an aspartyl protease.

31. The method of claim 30, wherein the aspartyl protease is cathepsin D.

32. The method of any one of claims 1-31, wherein the preparation is a cell culture supernatant of a cell culture expressing the recombinant polypeptide.

33. The method of claim 32, wherein the cell culture is a prokaryotic or eukaryotic cell culture.

34. The method of claim 32, wherein the cell culture is a mammalian cell culture.

35. The method of claim 34, wherein the mammalian cell culture comprises Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK 293) cells, Vero cells, baby hamster kidney (BHK) cells, HeLa cells, CV1 monkey kidney cells, Madin-Darby Canine Kidney (MDCK) cells, 3T3 cells, a myeloma cell line, COS cells, PC12 cells, or W138 cells.

36. The method of claim 34, wherein the mammalian cell culture comprises CHO cells.

37. The method of any one of claims 1-36, wherein the recombinant polypeptide is an Fc-containing polypeptide.

38. The method of claim 37, wherein the Fc-containing polypeptide is an antibody, an antibody fragment comprising an Fc region, an antibody derivative, or an antibody-drug conjugate.

39. The method of any one of claims 2-14 and 16-38, wherein the solid support is an affinity chromatography resin comprising a ligand that binds an Fc-containing polypeptide, an antibody heavy chain, or an antibody light chain.10006-US01-PRI40. The method of any one of claims 2-14 and 16-38, wherein the solid support is an affinity chromatographic resin comprising a chelating ligand that binds an amino acid residues of the recombinant polypeptide.

41. A method of producing a preparation comprising an anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody, said method comprising:contacting a cell culture supernatant comprising the anti-GIPR antibody and host cell proteases with a solution comprising sodium deoxy cholate, wherein the sodium deoxy cholate disrupts anti-GIPR antibody-host cell protease interactions in the preparation;loading the contacted culture supernatant onto an affinity chromatography column; washing the chromatography column, after said loading, with one or more wash solutions to remove the host cell proteases from the chromatography column; andeluting the anti-GIPR antibody from the chromatography column to produce the preparation comprising the anti-GIPR antibody.